微染色体维持蛋白 7 和增殖细胞核抗原是口腔鳞状细胞癌患者可靠的预后标志物：免疫组化研究。
Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study.
机构信息
Division of Organ Pathology, Department of Microbiology and Pathology, Faculty of Medicine, Tottori University, Yonago, Japan.
出版信息
J Oral Pathol Med. 2010 Apr;39(4):328-34. doi: 10.1111/j.1600-0714.2009.00861.x. Epub 2010 Feb 2.
BACKGROUND
Minichromosome maintenance (MCM) proteins act as the origin licensing machinery that regulates initiation of DNA replication. Geminin is a licensing repressor and prevents reinitiation of DNA replication by blocking reloading of MCM proteins at replication origins. Recent studies have proposed that MCM7 and geminin may be sensitive proliferative and prognostic markers of various malignant tumors. This study aimed to analyze the expression of MCM7 and geminin to clarify pathobiological significance in human oral squamous cell carcinomas (OSCCs).
METHODS
We performed immunohistochemical analysis on 10 specimens of normal oral epithelia, 50 lesions with dysplasia and 113 OSCCs. Labeling indices (LIs) for MCM7, geminin and Ki-67 were evaluated, comparing with clinicopathological profiles.
RESULTS
The mean LIs for MCM7 were 29.2% for normal epithelia, 32.2% for dysplasias, and 51.1% for OSCCs; the value was significantly higher in the last than in the former two (P < 0.01). The mean LIs for geminin were 6.8% for normal epithelia, 9.2% for dysplasias, and 21.3% for OSCCs; the value was significantly higher in the OSCCs (P < 0.01). The MCM7 LIs were correlated with the histological grade of OSCCs, in which the highest LIs were noted in the poorly differentiated type (P < 0.01). The survival rate was significantly lower in patients with a higher MCM7 LI (>49.5%) than in those with a lower LI (P < 0.05) at stage III-IV. However, the survival rate in the patients with a higher geminin LI (>19.5%) was significantly higher than in those with a lower LI (P < 0.05) at stage IV.
背景
微小染色体维持（MCM）蛋白作为调节 DNA 复制起始的原点许可机制发挥作用。增殖细胞核抗原（Geminin）是一种许可抑制剂，通过阻止 MCM 蛋白在复制原点的再装载，防止 DNA 复制的再起始。最近的研究表明，MCM7 和增殖细胞核抗原（Geminin）可能是各种恶性肿瘤敏感的增殖和预后标志物。本研究旨在分析 MCM7 和增殖细胞核抗原（Geminin）的表达，以阐明其在人类口腔鳞状细胞癌（OSCC）中的病理生物学意义。
方法
我们对 10 例正常口腔上皮、50 例发育不良病变和 113 例 OSCC 标本进行了免疫组织化学分析。评估了 MCM7、增殖细胞核抗原（Geminin）和 Ki-67 的标记指数（LI），并与临床病理特征进行了比较。
结果
MCM7 的平均 LI 分别为正常上皮的 29.2%、发育不良的 32.2%和 OSCC 的 51.1%；最后一个数值明显高于前两个（P<0.01）。增殖细胞核抗原（Geminin）的平均 LI 分别为正常上皮的 6.8%、发育不良的 9.2%和 OSCC 的 21.3%；OSCC 中的数值明显更高（P<0.01）。MCM7 的 LI 与 OSCC 的组织学分级相关，其中分化程度较差的类型 LI 最高（P<0.01）。在 III-IV 期，LI 较高（>49.5%）的患者的生存率明显低于 LI 较低的患者（P<0.05）。然而，LI 较高（>19.5%）的患者的生存率在 IV 期明显高于 LI 较低的患者（P<0.05）。
Zotero 插件